- Home
- UROY vs PRTA Comparison
UROY vs PRTA Comparison
Compare UROY & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UROY
- PRTA
- Stock Information
- Founded
- UROY 2017
- PRTA 2012
- Country
- UROY Canada
- PRTA Ireland
- Employees
- UROY N/A
- PRTA N/A
- Industry
- UROY
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- UROY
- PRTA Health Care
- Exchange
- UROY Nasdaq
- PRTA Nasdaq
- Market Cap
- UROY 336.8M
- PRTA 472.1M
- IPO Year
- UROY N/A
- PRTA N/A
- Fundamental
- Price
- UROY $3.15
- PRTA $8.20
- Analyst Decision
- UROY Strong Buy
- PRTA Buy
- Analyst Count
- UROY 2
- PRTA 10
- Target Price
- UROY $4.00
- PRTA $14.86
- AVG Volume (30 Days)
- UROY 2.6M
- PRTA 1.2M
- Earning Date
- UROY 07-16-2025
- PRTA 08-04-2025
- Dividend Yield
- UROY N/A
- PRTA N/A
- EPS Growth
- UROY N/A
- PRTA N/A
- EPS
- UROY N/A
- PRTA N/A
- Revenue
- UROY $11,285,840.00
- PRTA $10,341,000.00
- Revenue This Year
- UROY $228.36
- PRTA N/A
- Revenue Next Year
- UROY N/A
- PRTA $389.77
- P/E Ratio
- UROY N/A
- PRTA N/A
- Revenue Growth
- UROY N/A
- PRTA N/A
- 52 Week Low
- UROY $1.43
- PRTA $4.32
- 52 Week High
- UROY $3.30
- PRTA $22.83
- Technical
- Relative Strength Index (RSI)
- UROY 65.88
- PRTA 58.73
- Support Level
- UROY $2.51
- PRTA $8.05
- Resistance Level
- UROY $2.87
- PRTA $8.73
- Average True Range (ATR)
- UROY 0.16
- PRTA 0.38
- MACD
- UROY 0.05
- PRTA -0.05
- Stochastic Oscillator
- UROY 82.05
- PRTA 47.62
About UROY Uranium Royalty Corp.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is the investment in a portfolio of uranium interests.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.